Analytical performance of a monoclonal digoxin assay by dry chemistry on the Vitros 950

REFERENCES

• Bresnahan JF, Vliesta RE. Series on pharma-cology in practice 3. Digitalis glycosides. Mayo Clin Proc 1979; 54: 675–84.
   PubMed Web of Science ®Google Scholar
• Ried LD, Horn JR, McKenna DA. Therapeutic drug monitoring reduces toxic drug reactions: a meta-analysis. Ther Drug Monitor 1990; 12: 72–8.
   Google Scholar
• Tietz NVV editor. Textbook of clinical chemistry, 2nd ed. Philadelphia: WB Saunders; 1994. 1121 pp.
   Google Scholar
• Howanitz PJ, Steidel SJ. Digoxin therapeutic drug monitoring practices: a College of American Pathologists Q-probes study of 666 institutions and 18676 toxic levels. Arch Pathol Lab Med 1993; 117: 684–90.
   Google Scholar
• Piergies AA, Worwag EM, Atkinson AJ Jr. A concurrent audit of high digoxin plasma levels. Clin Pharmacol Ther 1994; 55: 353–8.
   Google Scholar
• Lewis RP. Clinical use of serum digoxin concen-trations. Am J Cardiol 1992; 69: 976–1076.
   Google Scholar
• Soldin SJ. Digoxin-issues and controversies. Clin Chem 1986; 32: 5–12.
   PubMedGoogle Scholar
• Bednarczyk B, Soldin SJ, Gasinska I, D'Costa M, Perrot L. Improved receptor assay for measuring digoxin activity. Clin Chem 1988; 34: 393–7.
   Google Scholar
• Antman EM, Wemger TL, Butler VP, Haber E, Smith TIM. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin specific Fab antibody fragments. Final report of a multicenter study. Circulation 1990; 81: 1744–52.
   Google Scholar
• Stone JA, Soldin SJ. An update on digoxin. Clin Chem 1989; 35: 1326–31.
   PubMed Web of Science ®Google Scholar
• Valdes R Jr. Endogenous digoxin-like immuno-reactive factors: impact on digoxin measurements and potential physiological implications. Clin Chem 1985; 31: 1525–32.
   Google Scholar
• Graves SW, Brown B, Valdes R Jr. An endogen-ous digoxin-like substance in patients with renal impairment. Ann Intern Med 1983; 9: 604–8.
   Google Scholar
• Dodds HM, Norris RLG, Johnson AG, Pond SM. Evaluation and comparison of the Tdx II, Stratus, and Opus digoxin assays. Ther Drug Monitor 1995; 17: 68–74.
   Google Scholar
• Miller JJ, Straub RW Jr, Valdes R Jr. Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS: 180. Ther Drug Monitor 1996; 18: 65–72.
   Google Scholar
• Jortani SA, Valdes R Jr.. Digoxin and its related endogenous factors. Clin Rev Clin Lab Sci 1997; 34: 225–74.
   Web of Science ®Google Scholar
• Azzazy HME, Duh SH, Maturen A, Schaller E, Shaw L, Grimaldi R, Shock G, Christenson RH. Multicenter study of Abbott AxSYM Digoxin II assay and comparison with 6 methods for susceptibility to digoxin-like immunoreactive fac-tors. Clin Chem 1997; 43: 1635–40.
   PubMed Web of Science ®Google Scholar
• Krower JS. Observations on comparisons of within-run and day-to-day precision [Letter]. Clin Chem 1981; 27: 202. (An equation corrected in Clin Chem 1981; 27: 629).
   Google Scholar
• Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Scientific, 1994.
   Google Scholar
• Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; i: 307— 10.
   Google Scholar
• Fraser CG, Petersen PH, Ricos C, Haeckel R. Proposed quality specifications for the imprecision and inaccuracy of analytical systems for clinical chemistry. Eur J Clin Chem Biochem 1992; 30: 311–17.
   PubMedGoogle Scholar
• Graves SW, Valdes R Jr, Brown BDA, Knight AB, Craig HR. Endogenous digoxin-immuno-reactive substance in human pregnancies. Clin Endocrinol Metab 1984; 58: 740–51.
   Google Scholar
• Jiang F, Wilhite TR, Smith CH, Landt M. A new digoxin immunoassay substantially free of inter-ference by digoxin immunoreactive factor. Ther Drug Monitor 1995; 17: 184–8.
   Google Scholar
• Yatscoff RW, Desjardins PRE, Dalton JG. Digoxin-like immunoreactivity in the serum of neonates and uremic patients, as measured in the Abbott Tdx. Clin Chem 1984; 30: 588.
   Google Scholar
• Naomi S, Graves S, Lazarus M, Williams GH, Hollemberg NK. Variation in apparent serum digitalis like factor levels with different digoxin antibodies: the "immunochemical fingerprint". Am J Hypertens 1991; 4: 795–801.
   Google Scholar
• Crossey MJ, Dasgupta A. Effects of digoxin-like immunoreactive substances and digoxin FAB antibodies on the new digoxin microparticle enzyme immunoassay. Ther Drug Monitor 1997; 19: 185–90.
   Google Scholar
• Rainey PM. Effect of digoxin immuno fab (ovine) in digoxin immunoassays. Am J Clin Pathol 1989; 12: 288–92.
   Google Scholar
• Lucena ?, Andrade RG, Fraile JM, Alcantara R, Gonzalez-Correa FS. Endogenous digoxin-like substance in liver failure. Int J Clin Pharmcol Ther 1994; 32: 567–9.
   Google Scholar
• Luke M, Dasgupta A. Digitoxin-like and digoxin-like immunoreactivities in sera of patients with uremia and liver disease as measured by fluores-cence polarization immunoassays; poor correlation between digitoxin-like and digoxin-like immuno-reactivities. Ther Drug Monitor 1997; 19: 230–5.
   Google Scholar
• Matheke ML, Valdes R Jr.. Antibody specificity reduces interference by endogenous digoxin-like immunoreactive factors. J Clin Immunoassay 1989; 12: 115–21.
   Google Scholar
• Whay BA, Wilhite TR, Miller R, Smith CH, Landt M. Vitros digoxin immunoassay evaluated for interference by digoxin-like immunoreactive factors. Clin Chem 1998; 44: 1339–40.
   Google Scholar
• Nanja AA, Greenway DC. Falsely raised plasma digoxin concentrations in liver disease. Br Med J 1985; 290: 432–5.
   Google Scholar
• Skogen WF, Rea MR, Valdes R Jr. Improved interassay correlation of digoxin results in patients with and without renal failure by elimination of digoxin-like imunoreactive factors. Clin Chem 1987; 33: 837–9.
   Google Scholar